Abstract:Background: Tigecycline, the first glycylcycline to be approved by the US Food and Drug Administration, is a structural analogue of minocycline that was designed to avoid tetracycline resistance mediated by ribosomal protection and drug efflux. It is indicated for the treatment of complicated skin and skin-structure infections and complicated intra-abdominal infections and is available for intravenous administration only. Objective: This article summarizes the in vitro and in vivo activities and pharmacologic and pharmacokinetic properties of tigecycline, and reviews its clinical efficacy and tolerability profile. Methods: Relevant information was identified through a search of MEDLINE (1966-April 2006), Iowa Drug Information Service (1966-April 2006), and International Pharmaceutical Abstracts (1970-April 2006) using the terms tigecycline, GAR-936, and glycylcycline. Also consulted were abstracts and posters from meetings of the Infectious Diseases Society of America and the Interscience Conference on Antimicrobial Agents and Chemotherapy (1999-2006) and documents provided for formulary consideration by the US manufacturer of tigecycline. Results: Like the tetracyclines, tigecycline binds to the 30S subunit of bacterial ribosomes and inhibits protein synthesis by preventing the incorporation of amino acid residues into elongating peptide chains. In vitro, tigecycline exhibits activity against a wide range of clinically significant gram-positive and gram-negative bacteria, including multidrug-resistant strains (eg, oxacillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, extended-spectrum beta-lactamase-producing Enterobacteriaceae), and anaerobes (eg, Bacteroides spp). In pharmacokinetic studies in human adults, tigecycline had a large Vd (7-9 L/kg), was moderately bound to plasma protein (71%-89%), had an elimination t(1/2) of 42.4 hours, and was eliminated primarily by biliary/fecal (59%) and renal (33%) excretion. Dose adjustment did not appear to be necessary based on age, sex, renal function, or mild to moderate hepatic impairment (Child-Pugh class A-B). In patients with severe hepatic impairment (Child-Pugh class C), the maintenance dose should be reduced by 50%. In 4 Phase III clinical trials in patients with complicated skin and skin-structure infections and complicated intra-abdominal infections, tigecycline was reported to be noninferior to its comparators (vancomycin + aztreonam in 2 studies and imipenem/cilastatin in 2 studies), with clinical cure rates among clinically evaluable patients of >80% (P < 0.001 for noninferiority). The most frequently reported (> or =5 %) adverse events with tigecycline were nausea (28.5%), vomiting (19.4%), diarrhea (11.6%), local IV-site reaction (8.2%), infection (6.7%), fever (6.3%), abdominal pain (6.0%), and headache (5.6%). The recommended dosage of tigecycline is 100 mg IV given as a loading dose, followed by 50 mg IV g12h for 5 to 14 days. Conclusions: In clinical trials, tigecycline was effective for the treatment of complicated skin and skin-structure infections and complicated intra-abdominal infections. With the exception of gastrointestinal adverse events, tigecycline was generally well tolerated. With a broad spectrum of activity that includes multidrug-resistant gram-positive and gram-negative pathogens, tigecycline may be useful in the treatment of conditions caused by these pathogens.

In Vitro Activity of Tigecycline Against 414 Gram-Negative and Gram-Positive Clinical Isolates

Resistance of Clinical Isolated Gram Negative Bacilli to Tigecycline

In vitro activities of tigecycline against clinical isolates from Shanghai, China

Genotypic characterization and in vitro activities of tigecycline and polymyxin B for members of the Enterobacteriaceae with decreased susceptibility to carbapenems.

MALDI-TOF MS Combined with AUC Method for Tigecycline Susceptibility Testing in Escherichia Coli

The Resistance of Multi-Drug Resistant Acinetobacter Baumannii to Tigecycline

Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial

Tigecycline Susceptibility And The Role Of Efflux Pumps In Tigecycline Resistance In Kpc-Producing Klebsiella Pneumoniae

Evaluation of different tigecycline susceptibility testing methods for Acinetobacter baumannii

In vitro activity of tigecycline and minocycline against Van M-type vancomycin-resistantEnterococcus faecium

Use of antibacterial consumer products containing quaternary ammonium compounds and drug resistance in the community

In Vitro Activities Of Tedizolid Compared With Other Antibiotics Against Gram-Positive Pathogens Associated With Hospital-Acquired Pneumonia, Skin And Soft Tissue Infection And Bloodstream Infection Collected From 26 Hospitals In China

In vitro activities of tebipenem pivoxil against clinical isolates

In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China

Comparative Evaluation of Tigecycline Susceptibility Testing Methods for Acinetobacter Baumannii and Enterobacteriaceae

Evaluation of the Capability of Four Tests for Identification of the in Vitro Susceptibility of Tigecycline Against Acinetobacter and Enterobacteriaceae Isolates

[In Vitro Activity of Daptomycin and Other Antimicrobial Agents Against 499 Strains of Gram-Positive Cocci Causing Bloodstream Infection].

Tigecycline Resistance in Multidrug-Resistant Acinetobacter baumannii

In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii

In vitro activity of tigecycline against resistant micro-organisms isolated from burn patients

Tigecycline: a glycylcycline antimicrobial agent